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ABSTRACT: In order to identify new anticancer compounds
from nature, a prefractionated library derived from Australian
endemic plants was generated and screened against the prostate
cancer cell line LNCaP using a metabolic assay. Fractions from
the seeds, leaves, and wood of Anopterus macleayanus showed
cytotoxic activity and were subsequently investigated using a
combination of bioassay-guided fractionation and mass-directed
isolation. This led to the identiﬁcation of four new diterpenoid
alkaloids, 6α-acetoxyanopterine (1), 4′-hydroxy-6α-acetoxya-
nopterine (2), 4′-hydroxyanopterine (3), and 11α-benzoyla-
nopterine (4), along with four known compounds, anopterine
(5), 7β-hydroxyanopterine (6), 7β,4′-dihydroxyanopterine (7),
and 7β-hydroxy-11α-benzoylanopterine (8); all compounds
were puriﬁed as their triﬂuoroacetate salt. The chemical
structures of 1−8 were elucidated after analysis of 1D/2D NMR and MS data. Compounds 1−8 were evaluated for cytotoxic
activity against a panel of human prostate cancer cells (LNCaP, C4-2B, and DuCaP) and nonmalignant cell lines (BPH-1 and
WPMY-1), using a live-cell imaging system and a metabolic assay. All compounds showed potent cytotoxicity with IC50 values of
<400 nM; compound 1 was the most active natural product from this series, with an IC50 value of 3.1 nM toward the LNCaP cell
line. The live-cell imaging assay on 1−8 showed a concentration- and time-dependent eﬀect on the cell morphology and
proliferation of LNCaP cells.
The genus Anopterus belongs to the plant familyEscalloniaceae and consists of only two species, Anopterus
macleayanus and A. glandulosus, which are both found only in
Australia. A. macleayanus F. Muell., also known as Queensland
Laurel or Macleay Laurel, is a tree growing to a height of up to
16 m and is found in the subtropical rainforests of Southern
Queensland and Northern New South Wales. A. glandulosus
Labill., also known as Native Laurel or Tasmanian Laurel, is a
small tree (2−4 m) that grows in the mountain regions of
Tasmania.1
Only three chemical investigations of A. glandulosus and A.
macleayanus have been reported; these include Denne et al. in
1972,2 Hart et al. in 1976,3,4 and Johns et al. in 1985.5 Those
studies yielded several novel ent-kaurenoid alkaloids, belonging
to the C20 diterpenoid alkaloid class. This structure class is
currently divided into three groupings that include the atisane,
kaurane, and bisditerpene alkaloid classes, which can all be
further characterized according to the position and number of
additional C−C or N−C bonds. For example, the kaurane class
includes secondary metabolites that contain veatchine, napel-
line, and anopterine scaﬀolds.6 The distribution of C20
diterpenoid alkaloids in nature is limited, with all examples of
this chemotype having been isolated from only eight plant
genera and ﬁve plant families.6 The anopterine structure class
has only been isolated from Anopterus species and is unique due
to its C-14/C-20 linkage,6 which was ﬁrst identiﬁed by X-ray
crystallography.2 Currently, there are a total of nine natural
products based on the anopterine scaﬀold described.5,7
Biological investigations of Anopterus plants have been
previously reported, with extracts of diﬀerent samples of both
A. macleayanus and A. glandulosus tested for cytotoxicity and
subsequently pursued by the National Cancer Institute (NCI),
USA (1961−1981).8 These two species have also been
investigated by the Commonwealth Scientiﬁc and Industrial
Research Organization (CSIRO) as part of a drug discovery
screening campaign in collaboration with the NCI; this work
was published in 1990.9 In the CSIRO study, A. macleayanus
extracts exhibited cardiovascular, diuretic, and antitumor [L-
1210 lymphoid leukemia in mice and human epidermoid
carcinoma of nasopharynx cells (KB)] activities, but showed no
antispasmodic or anticonvulsing eﬀects.9 A. glandulosus extracts
showed cardiovascular activity and antitumor eﬀects against
Dunning ascites leukemia and P388 lymphocytic leukemia
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mouse models as well as cytotoxicity against the KB cell line.9
In 1987, Wall et al., through NCI-funded research, evaluated
the antitumor activity of A. glandulosus leaves and twig extracts
(in vitro using the KB cell line and in vivo using an iv-implanted
murine P388 leukemia model).10 With the exception of one
compound (11α-destigloylanopterine), which was considered
inactive, all other anopterine analogues exhibited considerable
in vitro cytotoxicity (ED50 values ranging from 1 to 50 ng/
mL).10 The in vivo bioactivity study of the plant extracts by
Wall et al. in the P388 leukemia model showed promising
dose−response data; however, the activity was lost when pure
compounds were tested.10 It was suggested by the authors that
minor alkaloids might be responsible for the activity of the
plant extracts.10
Owing to a continuing interest in the discovery and
development of new anticancer compounds from nature,11−13
we have created a prefractionated library derived from
Australian endemic plants and screened this unique library
for cytotoxic activity against the LNCaP cell line (human
prostate carcinoma) using a metabolic assay. Three fractions
derived from the seeds, leaves, and wood extracts of A.
macleayanus were found to display potent activity and were
selected for further investigations.
This paper describes the bioassay-guided fractionation, mass-
directed isolation, and structure elucidation of four new and
four known anopterine analogues from A. macleayanus.
Furthermore, the in vitro cytotoxicity evaluation of all
compounds toward prostate cancer cell lines (LNCaP, C4-2B,
and DuCaP) and nonmalignant cell lines (BPH-1 and WPMY-
1) is also reported.
■ RESULTS AND DISCUSSION
Thirty-eight Australian endemic plant samples were selected for
the creation of the plant-derived prefractionated library, based
on published phytochemical studies from the CSIRO.9 The
MeOH extract for each plant specimen was prepared using a
small quantity of air-dried and ground material. These 38
MeOH extracts were fractionated using reversed-phase
analytical HPLC and a reported lead-like enhanced fractiona-
tion process,14 which yielded 38 optimized fractions that were
tested for their cytotoxic activity toward the LNCaP cell line
using a metabolic assay.
The fractions derived from the seeds, leaves, and wood of A.
macleayanus all showed potent activity (>70% inhibition at 10
μg/mL) and were selected for further investigations. A portion
of the MeOH extract derived from the large-scale extraction of
the seeds (10 g) was subjected to semipreparative C18 HPLC
(MeOH/H2O/0.1% TFA) and yielded eight fractions, which
were tested for cytotoxicity. LCMS data for the active fractions
indicated UV-active compounds that contained prominent ions
in the (+)-ESI mode at m/z 542, 558, 564, 574, 580, and 584,
suggesting the presence of alkaloids. The active fractions
obtained from the semipreparative HPLC did not yield
suﬃcient quantities of pure compounds to allow structure
determination. Owing to the identiﬁcation of alkaloids, the
remaining MeOH extract was subjected to an alkaloid
extraction and puriﬁed using phenyl HPLC (MeCN/H2O/
0.1% TFA) to aﬀord the triﬂuoroacetate salt of the known
alkaloid 7β-hydroxy-11α-benzoylanopterine (8). In order to
isolate more of the bioactive compounds, it was decided to
investigate the leaves and wood of A. macleayanus, which were
more plentiful. Fortuitously, the LCMS data from both the
wood and leaf extracts indicated that these samples contained
the same ions as the seeds, with an additional ion at m/z 600
detected in the leaves.
The wood (65 g) of A. macleayanus was sequentially
extracted with CH2Cl2 and MeOH. The CH2Cl2/MeOH
extracts were combined, evaporated, then resuspended in
MeOH/H2O, and subjected to an alkaloid extraction followed
by a liquid/liquid partition using CH2Cl2/H2O. Subsequent
fractionations of the organic layer using semipreparative phenyl
HPLC (MeOH or MeCN/H2O/0.1% TFA) aﬀorded the
triﬂuoroacetate salts of the new alkaloids 6α-acetoxyanopterine
(1), 4′-hydroxyanopterine (3), and 11α-benzoylanopterine (4),
along with the known alkaloids anopterine (5), 7β-hydrox-
yanopterine (6), 7β,4′-dihydroxyanopterine (7), and 7β-
hydroxy-11α-benzoylanopterine (8).
Chart 1
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The leaves (270 g) of A. macleayanus were extracted in an
identical manner to the wood material, and the resulting
CH2Cl2/MeOH extract was subjected to chlorophyll removal
via an n-hexane/H2O partition. The aqueous layer was
subsequently extracted with CH2Cl2, and the organic phase
was fractionated using phenyl HPLC (MeOH or MeCN/H2O/
0.1% TFA) and yielded the triﬂuoroacetate salts of one
additional new alkaloid, 4′-hydroxy-6α-acetoxyanopterine (2),
along with larger quantities of 6α-acetoxyanopterine (1).
Compound 1 was obtained as a stable yellow gum. A
molecular formula of C33H45NO8 for the free base of 1 was
assigned following analysis of both NMR and (+)-HRESIMS
data. The 1H NMR spectrum of 1 displayed signals for 10
methines (δH 2.60, 3.05, 3.30, 4.24, 5.12, 5.22, 5.24, 5.54, 6.77,
7.26), six methylenes (δH 1.66/2.12, 1.89/2.72, 2.23/2.88,
2.22/2.75, 3.74/4.52, 4.96/5.13), ﬁve methyls (δH 1.02, 1.75,
1.76, 1.83, 1.90), one O-acetyl (δH 2.29), and an N-methyl (δH
3.29). The 13C NMR data that was obtained from the HSQC/
HMBC spectra showed signals for 10 methine carbons (δC
53.5, 53.6, 54.8, 70.4, 138.4, 139.6 including four oxymethine
carbons δC 65.6, 69.9, 72.8, 73.5), six methylene carbons (δC
36.2, 39.3, 40.7, 43.6, 64.6, 109.4), six methyl carbons (δC 11.6,
12.3, 14.4, 14.7, 21.8, 23.2), 10 nonprotonated carbons (δC
36.3, 49.9, 53.1, 75.8, 128.1, 128.6, 148.2, 166.2, 167.6, 169.0),
and one N-methyl group (δC 47.3).
Analysis of the 1H−1H COSY spectrum, in combination with
the 1H−1H coupling constants, identiﬁed two spin systems.
The ﬁrst system included protons at δH 2.60 (H-9), 5.54 (H-
11), 5.24 (H-12), 3.30 (H-13), and 3.05 (H-14). HMBC
correlations between H-11 (δH 5.54) and the quaternary carbon
at δC 49.9 (C-8) and from H-14 (δH 3.05) to the carbon at C-9
(δC 53.5) allowed construction of ring C (Figure 1). The
1H
NMR spectrum of 1 also displayed signals corresponding to
two nonequivalent oleﬁnic methine protons (δH 6.77 and 7.26)
and four nonequivalent deshielded methyl groups (δH 1.75,
1.76, 1.83, and 1.90). The 1H−1H COSY data (Figure 1) in
conjunction with the multiplicity and coupling constants of the
oleﬁnic methine protons at δH 6.77 (br q, J = 6.7 Hz) and 7.26
(br q, J = 7.0 Hz) indicated two identical groups that were each
associated with one oleﬁnic proton that was geminal to one
methyl group (δH 1.76, d, J = 6.7 Hz and δH 1.83, d, J = 7.0 Hz,
respectively). The HMBC data between the second deshielded
methyl of each group (δH 1.75 and 1.90), the carbonyl (δC
166.2 and 167.6), and the carbon bearing both oleﬁnic methine
protons and the vicinal methyl were used to unambiguously
establish two 2-methyl-2-butenoate moieties.15 The coupling
constants and chemical shifts were typical for a tigloyl group,15
and this was further supported by comparison of the 1H/13C
NMR data of 1 with commercially available tiglic acid (Figures
S46 and S47, Supporting Information). The HMBC
correlations between the doublet of doublets resonating at δH
5.54 (H-11) and the tiglic carbonyl at δC 166.2 (C-1′) indicated
that a tigloyl group was attached at C-11. As shown in Figure 1,
the same process was applied with the proton at δH 5.24 (H-
12) and the second tigloyl group. The two broad singlets at δH
4.96/5.13 (H2-17) were assigned to an exocyclic methylene
group, forming a two-carbon bridge between C-13 and C-8 of
ring C, following HMBC and 1H−1H COSY data analysis.
Rings B and C were linked together via the correlations of the
methylene protons at C-15 (δH 2.23/2.88) with C-14 (δC 54.8)
and with the 1H−1H COSY correlations between the
methylene protons H2-7 (δH 1.89/2.72) and the methine
proton H-6 (δH 5.22). Ring A was identiﬁed using the second
spin system, which included the protons δH 2.22/2.75 (H2-1),
4.24 (H-2), and 1.66/2.12 (H2-3), as well as the HMBC
correlations from the angular methyl group (δH 1.02) to the
carbons at δC 36.3 (C-4) and 43.6 (C-3). The carbons C-5 (δC
75.8) and C-10 (δC 53.1) ﬁnalized the diterpenoid structure, as
protons from rings A and B showed strong 3JCH correlations to
these central carbons. A pair of diastereotopic protons (δH
3.74/4.52 and δC 64.6), a methine (δH 5.12 and δC 70.4), and a
methyl (δH 3.29 and δC 47.3) were all attached to a nitrogen
atom based on HMBC correlations (Figure 1). Furthermore,
HMBC correlations from the diastereotopic protons (δH 3.74/
4.52, H2-19) to C-3 (δC 43.6), C-4 (δC 36.3), C-5 (δC 75.8),
and the C-18 methyl group (δC 23.2) positioned the nitrogen-
containing bridge at C-4. The HMBC correlations between H-
20 (δH 5.12) and C-8 (δC 49.9) and C-13 (δC 53.6) established
the C-20/C-14 linkage. The HMBC correlations from H-20
(δH 5.12) to C-1 (δC 36.2), C-10 (δC 53.1), and C-5 (δC 75.8)
conﬁrmed the C-10/C-20 linkage. These spectroscopic data
indicated that 1 belonged to the C20 diterpenoid alkaloid
class.6,16 Comparison of the NMR data indicated that
compound 1 had a structure similar to anopterine (5), the
major compound previously reported from Anopterus species.3,5
The relative conﬁguration of 1 was determined on the basis of
ROESY experiments in both acetone-d6 and DMSO-d6. The
data in acetone-d6 showed correlations between H-9 and H-11,
and also between H-11 and H-12 and the methylene proton H-
15(β); H-6 showed a strong ROESY correlation to CH3-18.
These connectivities, along with ROESY correlations such as
H-3(β)/CH3-18, H-3(α)/CH3-18, H-13/H-20, H-20/N-CH3,
and H-19/CH3-18, indicated the relative conﬁguration of
compound 1 was identical to anopterine (5); however the OH-
5 orientation could not be assigned since this signal was not
observed in acetone-d6. In order to assign the orientation of
OH-5, NMR data for compound 1 in DMSO-d6 were collected.
Fortuitously, ROESY correlations were identiﬁed for all
exchangeable protons in DMSO-d6. These included ROESY
correlations between OH-5 (δH 5.38) and CH3-18, H-1(β), H-
3(β), H-6, and H-9 and also between the acetate methyl (δH
2.25) and CH3-18, H-6, H-19, and H-N-CH3 (δH 7.27). These
data allowed the orientation of OH-5 to be assigned as β. Thus,
the structure of 1 was determined to be 2α,5β-dihydroxy-6α-
acetoxy-11α,12α-ditigloyloxy-19,20-methylimino-14,20-cyclo-
Figure 1. Selected (A) HMBC and 1H−1H COSY and (B) ROESY
correlations of 6α-acetoxyanopterine (1).
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ent-kaur-16-ene, to which the trivial name 6α-acetoxyanopterine
(1) was assigned.
Compound 2 was assigned the molecular formula
C33H45NO9 (free base) following the analysis of the NMR
and (+)-HRESIMS data. The 1H NMR spectrum of 2 displayed
a high degree of homology with 1; however several notable
diﬀerences were identiﬁed. Speciﬁcally, one set of tigloyl signals
in 1 had been replaced with another small ester unit that
contained only one methyl (δH 1.73) in 2. In addition, the
vinylic proton resonated as a doublet of doublets of quartets at
δH 6.76 (ddq, J = 5.6, 5.6, 1.3 Hz, H-3′) in 2 instead of the
broad quartet that was observed in compound 1. Furthermore,
compound 2 possessed one more signal for a set of methylene
protons (δH 4.23/4.27, dd, J = 15.0, 5.6 Hz, H2-4′). As shown
in Figure 2, these methylene protons (H2-4′) showed 1H−1H
COSY correlations to a proton at δH 6.76 (H-3′) and HMBC
correlations to carbons at δC 12.4 (C-5′), 127.1 (C-2′), and
166.7 (C-1′). The HMBC correlation between H-11 and C-1′
positioned this small ester unit at C-11, while the tigloyl group
was attached to C-12 on account of a strong HMBC cross-peak
between H-12 and C-1″. From these data it was deduced that
the 11-tigloyl moiety of 1 has been replaced with an (E)-4-
hydroxy-2-methyl-2-butenoate (hydroxytigloyl4) unit in 2.
Thus, the structure of 2 was determined to be 2α,5β-
dihydroxy-6α-acetoxy-11α-(4′-hydroxytigloyloxy)-12α-tigloy-
loxy-19,20-methylimino-14,20-cyclo-ent-kaur-16-ene, to which
the trivial name 4′-hydroxy-6α-acetoxyanopterine (2) was
assigned.
Compound 3 was obtained as a stable yellow gum. The
molecular formula (C31H43NO8) of the free base of 3 was
established following interpretation of the NMR data and the
(+)-HRESIMS ion [M − TFA]+ at m/z 558.3067 (calcd
558.3061). Analysis of the 1D and 2D NMR spectra of 3
indicated it was also structurally related to anopterine (5), the
diﬀerence being the presence of four methyl group protons and
an additional set of methylene protons (δH 4.23/4.27) in 3,
compared to anopterine (5), which displayed ﬁve methyl
signals. The 1H−1H COSY correlations between the extra
methylene protons (δH 4.23/4.27, dd, J = 15.0, 5.8 Hz, H2-4′)
and H-3′ resonating at δH 6.75 (ddq, J = 5.8, 5.8, 1.3 Hz)
conﬁrmed the presence of a hydroxytigloyl group in 3 (Figure
3). The HMBC cross-peaks between H-11/C-1′ and H-12/C-
1″ allowed the hydroxytigloyl and tigloyl moieties to be
positioned at C-11 and C-12, respectively. Thus, the structure
of 3 was determined to be 2α,5β,6α-trihydroxy-11α-(4′-
hydroxytigloyloxy)-12α-tigloyloxy-19,20-methylimino-14,20-
cyclo-ent-kaur-16-ene, to which the trivial name 4′-hydrox-
yanopterine (3) was assigned.
The molecular formula of compound 4 was determined to be
C33H41NO7 (free base) following analysis of both the NMR
and MS data. The 1H and 13C NMR data of 4 closely matched
those of compound 3; however 4 contained resonances for a
benzoyl group (δH 7.49, 7.63, 7.94 and δC 129.0, 130.0, 130.7,
134.0) and lacked the signals of the hydroxy-tigloyl group
present in 3. The strong 3JCH correlations from the methine
protons at δH 7.94 (H-3′ and H-7′) and 5.72 (H-11) to the
same carbonyl at δC 165.5 indicated that the hydroxytigloyl
moiety in 3 had been replaced with a benzoyl group in 4
(Figure 4). Consequently, the structure of compound 4 was
assigned as 2α,5β,6α-trihydroxy-11α-benzoyloxy-12α-tigloy-
loxy-19,20-methylimino-14,20-cyclo-ent-kaur-16-ene and was
given the trivial name 11α-benzoylanopterine (4).
The four known compounds were identiﬁed as the TFA salts
of anopterine (5),2,3,5 7β-hydroxyanopterine (6),5 7β,4′-
dihydroxyanopterine (7),5 and 7β-hydroxy-11α-benzoylanop-
terine (8)5 following detailed spectroscopic/spectrometric data
analysis. Since compounds 5−8 were ﬁrst puriﬁed and reported
as their free bases,2,3,5 we obtained and analyzed 1D and 2D
NMR data to conﬁrm the chemical structures. Tables
containing the NMR data for compounds 5−8 as their free
base and TFA salt, as well as COSY, HSQC, and HMBC data,
can be accessed in the Supporting Information (Figures S25−
S45). Only minor NMR diﬀerences were identiﬁed between the
free base and TFA salt, with the exception of carbon and
hydrogen atoms that are in close proximity to the nitrogen
atom.
The structures of 7β-hydroxyanopterine (6) and 7β,4′-
dihydroxyanopterine (7) were initially misassigned by Hart et
al. in 1976 since only 1H NMR data were recorded for these
molecules and subsequently compared with that of anopterine
for the structure determination and assignment of both 6 and
7.4 The chemical structures of both 6 and 7 were corrected by
Johns et al. in 1985,5 using 1D and 2D NMR data. However,
our HMBC data for 6 and 7 showed that C-6, C-7, C9, and C-
10 had been misassigned by Johns et al. The full NMR
Figure 2. Selected HMBC and 1H−1H COSY correlations of 4′-
hydroxy-6α-acetoxyanopterine (2).
Figure 3. Selected HMBC and 1H−1H COSY correlations of 4′-
hydroxyanopterine (3).
Figure 4. Selected HMBC and 1H−1H COSY correlations of 11α-
benzoylanopterine (4).
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assignments can be accessed in the Supporting Information
(Figures S31−40).
The free base of 7β-hydroxy-11α-benzoylanopterine (8) was
also only partially characterized (1H NMR and MS data only)
in the original publication.5 We report the full NMR
assignment (Figures S41−45, Supporting Information) of the
TFA salt of 7β-hydroxy-11α-benzoylanopterine (8).
Finally, UV data for the known compounds were not
reported in the original publications; hence we have included
this data along with additional [α]D data in the Experimental
Section of this paper.
Compounds 1−8 were evaluated for their cytotoxicity against
a panel of human cell lines, including the prostate cancer cell
lines LNCaP (lymph node metastasis, androgen-sensitive), C4-
2B (LNCaP-derivative, androgen-insensitive), and DuCaP
(metastatic prostate cancer, androgen-sensitive) and the
nonmalignant cell lines BPH-1 (human benign prostatic
hyperplasia) and WPMY-1 (human prostatic stromal myoﬁ-
broblast) using a metabolic assay and a live-cell imaging
experiment. Prior to screening, all compounds were reanalyzed
by 1H NMR spectroscopy and shown to be >95% pure. The
metabolic activity of alkaloids 1−8 against the panel of cell lines
(Table 3) showed that they were highly active toward the
prostate cancer cell lines, with IC50 values of <400 nM.
Compounds 1, 2, and 8 were the most active, with IC50 values
of 3.1, 10.9, and 6.7 nM against LNCaP cells, respectively.
Compounds 1−8 were also cytotoxic in the nonmalignant cell
lines BPH-1 and WPMY-1, which translated to small selectivity
indices (SI = IC50 cancer cells/IC50 noncancer cells). For
instance, the SI of compound 1 was 0.3 and 0.5 between the
LNCaP cells and the cell lines BPH-1 and WPMY-1,
respectively. Notably, the known anticancer drug vinblastine,
which inhibits microtubule functions,17−19 was also cytotoxic in
both malignant and nonmalignant cell lines (Table 3), raising
the possibility that compounds 1−8 speciﬁcally target
proliferating cells.
The eﬀect of compounds 1−8 on cell growth was also
evaluated using a live-cell imaging assay. Proliferation of
LNCaP cells was monitored in real time as a function of cell
conﬂuence, using an IncuCyte system (Figure 5 for compound
1 and Figures S48 and S49, Supporting Information for 2−8).
As illustrated in Figure 5A with 6α-acetoxyanopterine (1) as an
example, the conﬂuence of LNCaP cells decreased with
increasing concentrations of this compound, indicating that 1
inhibited cell growth and visibly reduced the cell number when
compared to the DMSO control. Morphologically, LNCaP cells
treated with 1 showed loss of cell−cell contacts, round cell
bodies, and burst cells with membrane blebbing, which are
typical signs of apoptosis (Figure 5B).20,21
Table 1. 1H NMR Spectroscopic Data for Compounds 1−4a
1 2 3 4
position δH (mult. J in Hz) δH (mult. J in Hz) δH (mult. J in Hz) δH (mult. J in Hz)
1 2.22, dd (14.6, 4.7) 2.21, br d (14.6) 2.18, dd (14.8, 4.9) 2.29, dd (14.6, 4.6)
2.75, br d (14.6) 2.72, br d (14.6) 2.68, br d (14.8) 2.80, ddd (14.6, 2.1, 2.1)
2 4.24, m 4.21, m 4.18, m 4.22, m
3 1.66, br d (14.3) 1.65, br d (14.3) 1.56, ddd (14.3, 2.0, 2.0) 1.59, ddd (14.3, 2.1, 2.1)
2.12, dd (14.3, 3.8) 2.08, m 2.08, m 2.08, m
6 5.22, br d (6.7) 5.17, br d (6.7) 4.16, d (5.4) 4.20, d (5.5)
7 1.89, br d (16.2) 1.86, br d (16.0) 2.09, m 2.09, m
2.72, dd (16.2, 6.7) 2.70, m 2.54, dd (14.9, 5.4) 2.62, dd (15.1, 5.5)
9 2.60, m 2.58, m 2.51, m 2.65, m
11 5.54, dd (6.1, 4.4) 5.55, dd (6.1, 4.4) 5.53, dd (6.1, 4.2) 5.72, dd (6.1, 4.4)
12 5.24, dd (6.1, 2.4) 5.24, m 5.23, dd (6.1, 2.1) 5.35, dd (6.1, 2.3)
13 3.30, m 3.29, m 3.22, m 3.29, m
14 3.05, m 3.18, m 2.88, m 2.91, m
15 2.23, ddd (18.6, 2.1, 2.1) 2.22, br d (18.7) 2.22, ddd (18.5, 2.1, 2.1) 2.27, br d (18.8)
2.88, br d (18.6) 2.83, br d (18.7) 2.83, br d (18.5) 2.92, br d (18.8)
17 4.96, m 4.95, m 4.95, m 4.99, m
5.13, m 5.13, m 5.11, m 5.15, m
18 1.02, s 1.01, s 1.21, s 1.23, s
19 3.74, m 3.68, br d (12.7) 3.39, br d (12.0) 3.44, br d (12.0)
4.52, m 4.41, br d (12.7) 4.43, br d (12.0) 4.47, br d (12.0)
20 5.12, m 5.10, m 4.89, m 4.98, m
N−CH3 3.29, s 3.23, s 3.00, s 3.05, s
3′ 6.77, br q (6.7) 6.76, ddq (5.6, 5.6, 1.3) 6.75, ddq (5.8, 5.8, 1.3) 7.94, m
4′ 1.76, d (6.7) 4.23, dd (15.0, 5.6) 4.23, dd (15.0, 5.8) 7.49, m
4.27 dd (15.0, 5.6) 4.27 dd (15.0, 5.8)
5′ 1.75, s 1.73, s 1.73, s 7.63, tt (7.6, 1.3)
6′ 7.49, m
7′ 7.94, m
3″ 7.26, br q (7.0) 7.26, br q (7.0) 7.25, br q (7.0) 7.25, br q (7.1)
4″ 1.83, d (7.0) 1.82, d (7.0) 1.83, d (7.0) 1.82, d (7.1)
5″ 1.90, s 1.90, s 1.90, s 1.86, s
2‴ 2.29, s 2.29, s
aSpectra recorded at 600 MHz in acetone-d6 at 30 °C.
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Wall et al.10 have reported the cytotoxity of the known
anopterine analogues (5−8) toward the KB cell line and
observed similar levels of activity. No mechanism of action
studies have been reported for this rare structure class;
however, the potent cytotoxicity warrants further biological
investigations.
Table 2. 13C NMR Spectroscopic Data for Compounds 1−4a
position 1 2 3 4
1 36.2 36.2 36.5 36.7
2 65.6 65.2 65.4 65.6
3 43.6 43.6 43.1 43.0
4 36.3 36.7 36.6 36.7
5 75.8 76.1 76.4 76.5
6 73.5 73.4 70.3 70.5
7 40.7 41.3 43.9 44.2
8 49.9 49.9 49.8 50.1
9 53.5 53.3 54.4 54.6
10 53.1 52.8 52.3 52.5
11 69.9 70.0 70.4 70.9
12 72.8 72.8 73.0 72.9
13 53.6 53.7 53.7 53.7
14 54.8 54.2 54.8 55.0
15 39.3 39.5 39.8 39.9
16 148.2 148.8 149.1 149.2
17 109.4 109.0 108.8 109.9
18 23.2 23.3 23.8 23.6
19 64.6 64.4 63.4 63.4
20 70.4 70.1 68.9 68.9
N-CH3 47.3 47.7 44.6 44.6
1′ 166.2 166.7 166.4 165.5
2′ 128.6 127.1 127.0 130.7
3′ 138.4 144.1 144.0 130.0
4′ 14.4 59.2 59.4 129.0
5′ 11.6 12.4 12.7 134.0
6′ 129.0
7′ 130.0
1″ 167.6 167.5 167.3 167.4
2″ 128.1 128.6 128.4 128.5
3″ 139.6 139.9 139.7 139.9
4″ 14.7 14.3 14.6 14.6
5″ 12.3 12.3 12.6 12.6
1‴ 169.0 169.7
2‴ 21.8 21.7
aSpectra recorded at 150 MHz in acetone-d6 at 30 °C;
13C chemical
shifts obtained from HSQC and HMBC data.
Table 3. Cytotoxic Activities (IC50 ± SD) of Compounds 1−8 against Human Cell Lines
a
IC50 ± SD (nM)
compound LNCaP C4-2B DuCaP BPH-1 WPMY-1
1 3.1 ± 1.8 6.2 ± 0.3 8.7 ± 0.5 11.5 ± 5.7 6.6 ± 0.5
2 10.9 ± 3.2 7.0 ± 2.3 9.9 ± 1.2 11.4 ± 2.8 9.6 ± 2.1
3 378.8 ± 85.8 339.8 ± 71.7 355.0 ± 55.9 177.3 ± 52.8 328.5 ± 18.6
4 190.3 ± 96.2 205.4 ± 63.9 153.5 ± 16.5 236.1 ± 12.9 140.5 ± 34.5
5 27.2 ± 13.2 45.0 ± 10.5 86.9 ± 8.4 29.6 ± 2.0 48.2 ± 5.4
6 50.8 ± 23.9 93.8 ± 6.0 55.7 ± 4.4 64.3 ± 12.3 86.0 ± 13.8
7 72.6 ± 18.3 134.6 ± 30.9 70.7 ± 12.4 133.7 ± 27.3 154.6 ± 35.3
8 6.7 ± 1.8 5.2 ± 0.3 4.1 ± 0.3 9.2 ± 1.9 4.9 ± 1.2
vinblastine 3.2 ± 0.1 2.4 ± 0.2 3.7 ± 0.7 3.8 ± 0.6 4.2 ± 0.6
aCell lines: LNCaP, human prostate cancer (lymph node metastasis, androgen-sensitive); C4-2B, bone metastatic LNCaP-derivative (androgen-
insensitive); DuCaP, metastatic prostate cancer (androgen-sensitive); BPH-1, human benign prostatic hyperplasia; WPMY-1, human prostatic
stromal myoﬁbroblast.
Figure 5. (A) Changes to cell conﬂuence and (B) cell morphology of
LNCaP cells after 72 h of treatment with indicated doses of 6α-
acetoxyanopterine (6-AA, 1), DMSO, or vinblastine (Vinb) monitored
using an IncuCyte real-time live-cell imaging system (scale bar 100
μm).
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■ EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations were
recorded on a JASCO P-1020 polarimeter (Easton, MD, USA). UV
spectra were recorded on a JASCO V-650 UV/vis spectrophotometer.
NMR spectra were recorded at 30 °C on a Varian 600 MHz Unity
INOVA spectrometer (Palo Alto, CA, USA). The 1H and 13C chemical
shifts were referenced to the solvent peaks for acetone-d6 at δH 2.05
and δC 29.9/206.7 and for DMSO-d6 at δH 2.50 and δC 39.5. Standard
parameters were used for the 2D NMR experiments, which included
HSQC (1JCH = 140 Hz) and HMBC (
nJCH = 8.0 Hz). Phenomenex
solid-phase extraction (SPE) cartridges (10 × 50 mm, nylon frit,
Torrance, CA, USA) were used for small-scale plant extraction.
LRESIMS data were recorded on a Waters LCMS system (Milford,
MA, USA) equipped with a Phenomenex Luna C18 column (3 μm, 100
Å, 50 × 4.6 mm), a PDA detector, and a ZQ ESI mass spectrometer.
HRESIMS were recorded on a Bruker MicrOTof-Q spectrometer
(Billerica, MA, USA) with the Dionex UltiMate 3000 micro LC
system, ESI mode (Sunnyvale, CA, USA). All solvents used for
chromatography, [α]D, UV, and MS were HPLC grade (Honeywell
Burdick & Jackson, Morristown, NJ, USA), and the H2O was Millipore
Milli-Q PF ﬁltered (Billerica, MA, USA). Phenomenex end-capped
Sepra C18 bonded silica (35−75 μm, 150 Å) was used for extract/
fraction preadsorption work, and the resulting material was packed
into an Alltech stainless steel guard cartridge (10 × 30 mm, Columbia,
MD, USA). A Waters 600 pump and controller ﬁtted with a Waters
996 PDA detector and Gilson 717 Plus autosampler (Middleton, WI,
USA) were used for semipreparative HPLC separations. A
Phenomenex C18 Onyx analytical HPLC column (130 Å, 100 × 4.6
mm) was used for the generation of the plant-derived fraction library.
A Thermo Fisher Scientiﬁc Betasil C18 column (5 μm, 100 Å, 150 ×
21.2 mm, Waltham, MA, USA) and a Thermo Fisher Scientiﬁc Betasil
phenyl column (5 μm, 143 Å, 150 × 21.2 mm) were used for
semipreparative HPLC. A Fritsch Universal Cutting Mill Pulverisette
19 (Idar-Oberstein, Germany) was used to grind the air-dried plant
material. An Edwards Instrument Company Bioline orbital shaker
(Narangba, Australia) was used for the large-scale plant extractions.
Tiglic acid was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Plant Material. Thirty-six of the 38 Australian endemic plant
samples were obtained from the Nature Bank biota library, which is
housed at the Eskitis Institute for Drug Discovery, Griﬃth University,
Brisbane, Australia.22 All samples were taxonomically identiﬁed by the
Queensland Herbarium, and voucher specimens have been deposited
at the Queensland Herbarium, Brisbane, Australia. Anopterus
macleayanus F.Muell leaf and wood samples were obtained from the
Burringbar Rainforest Nursery (Burringbar, Australia) during May of
2013. A voucher specimen (RAD071) has been deposited at the
Eskitis Institute for Drug Discovery, Griﬃth University, Brisbane,
Australia. The plant material was air-dried, ground to a ﬁne powder,
and stored at room temperature prior to extraction.
Generation of the Plant-Derived Prefractionated Library. A
small amount (300 mg) of air-dried and ground plant material from
each of the 38 samples was packed into an SPE cartridge, washed with
n-hexane (8 mL), and successively extracted with CH2Cl2 (10 mL) and
MeOH (8 mL). The MeOH extracts were dried, weighed, and
resuspended in DMSO in order to create a stock solution at 1 mg/100
μL. Liquid injections (100 μL) of each crude MeOH extract were
fractionated by HPLC using a C18 Onyx analytical column and a
gradient solvent method that has previously been reported.14 The
initial and previously published fractionation process resulted in the
collection of 11 fractions per extract;14 however we decided to collect
only one fraction (between 2.0 and 7.0 min) in order to simplify the
process and minimize cost and time expenditure.
LCMS Analysis. The active fractions were resuspended in MeOH
(1 mL), prior to LCMS injection (20 μL). The LCMS was performed
using an analytical Phenomenex Luna column and a gradient from
95% H2O (0.1% formic acid)/5% MeOH (0.1% formic acid) to 100%
MeOH (0.1% formic acid) in 10 min, at a ﬂow rate of 1 mL/min.
Large-Scale Extraction and Isolation. The ground seeds (10 g)
of A. macleayanus were sequentially extracted at room temperature
with CH2Cl2 (200 mL) and MeOH (200 mL × 3). The resulting
extracts were ﬁltered under gravity, dried under reduced pressure,
weighed, and stored at room temperature (CH2Cl2, 468 mg; MeOH,
1.9 g). A portion of the MeOH extract (1.7 g) was resuspended in
MeOH, preadsorbed to C18 silica, and packed into four separate
stainless steel guard cartridges, and each cartridge was subjected to
semipreparative HPLC using a C18 Betasil column at a ﬂow rate of 9
mL/min. Isocratic conditions of 10% MeOH (0.1% TFA)/90% H2O
(0.1% TFA) were initially performed for the ﬁrst 10 min, followed by a
linear gradient to 100% MeOH (0.1% TFA) in 40 min; then isocratic
conditions of 100% MeOH (0.1% TFA) were run for 10 min. Sixty
fractions (60 × 1 min) were collected from the start of the HPLC run.
Fractions from the ﬁrst HPLC run were all tested for activity toward
LNCaP cells. In order to minimize the number of fractions tested,
aliquots from ﬁve consecutive fractions were pooled and tested.
Fractions containing biological activity were analyzed by (±)-LRE-
SIMS and 1H NMR spectroscopy. The CH2Cl2 extract was also
subjected to the same puriﬁcation process, in an attempt to purify
more material. None of these HPLC runs yielded suﬃcient quantities
of pure compounds to allow structure determination or biology
testing. The remaining MeOH extract (200 mg) was subjected to a
modiﬁed separation protocol, which included an alkaloid extraction
using EtOAc/H2O (1:1, 200 mL × 3), with the H2O basiﬁed with
ammonia (pH = 10). The enriched alkaloid fraction was subjected to
semipreparative Betasil phenyl HPLC. Isocratic conditions of 10%
MeCN (0.1% TFA)/90% H2O (0.1% TFA) were initially performed
for the ﬁrst 5 min, followed by a linear gradient to 100% MeCN (0.1%
TFA) in 60 min, at a ﬂow rate of 9 mL/min. Sixty-ﬁve fractions (65 ×
1 min) were collected from the start of the HPLC run. Fractions were
analyzed by (±)-LRESIMS in order to detect the ions belonging to the
active fractions previously identiﬁed. Fractions 34−36 contained some
of the desired ions and were combined (m = 8.3 mg), dried, and
further puriﬁed by HPLC using a Betasil phenyl column with solvent
conditions consisting of a linear gradient from 35% MeCN (0.1%
TFA)/65% H2O (0.1% TFA) to 80% MeCN (0.1% TFA)/20% H2O
(0.1% TFA) in 90 min at a ﬂow rate of 9 mL/min. Manual collection
yielded one pure compound as its TFA salt, 7β-hydroxy-11α-
benzoylanopterine (8, tR = 19 min, 1.5 mg, Mw 579 (free base),
0.015% dry wt).
The air-dried and ground wood (65 g) of A. macleayanus was
sequentially extracted at room temperature with CH2Cl2 (500 mL)
and MeOH (500 mL × 3). The CH2Cl2 and MeOH extractions were
combined and dried under reduced pressure to yield a crude extract
(∼8 g). The MeOH/CH2Cl2 extract was subjected to an alkaloid
extraction using EtOAc/H2O (1:1, 300 mL × 3), with the H2O
basiﬁed with ammonia (pH = 10). The enriched alkaloid fraction
(organic layer ∼1.6 g) was further puriﬁed with a liquid/liquid
partition using the system CH2Cl2/H2O (1:1, 500 mL × 3). The
CH2Cl2 extract (775 mg) was resuspended in MeOH, preadsorbed to
C18 silica, and packed into three separate stainless steel guard
cartridges, and each cartridge was subjected to semipreparative Betasil
phenyl HPLC. Linear gradient conditions from 20% MeOH (0.1%
TFA)/80% H2O (0.1% TFA) to 40% MeOH (0.1% TFA)/60% H2O
(0.1% TFA) were performed for the ﬁrst 20 min, followed by a linear
gradient to 80% MeOH (0.1% TFA)/20% H2O (0.1% TFA) for 30
min, then a gradient to 100% MeOH (0.1% TFA) in 10 min, at a ﬂow
rate of 9 mL/min. Sixty fractions (60 × 1 min) were collected from the
start of the HPLC run, and identical fractions from the three runs were
gathered. Fractions were analyzed by (±)-LRESIMS in order to detect
the ions belonging to the active fractions previously identiﬁed during
the investigations of the seed extract. Fractions 31 and 32 were
combined (m = 10.5 mg), dried, and further puriﬁed by HPLC using a
Betasil phenyl column with solvent conditions consisting of a linear
gradient from 30% MeCN (0.1% TFA)/70% H2O (0.1% TFA) to 80%
MeCN (0.1% TFA)/20% H2O (0.1% TFA) in 60 min at a ﬂow rate of
9 mL/min. Manual collection yielded two pure compounds as their
TFA salts, 7β,4′-dihydroxyanopterine (7, tR = 13 min, 1.6 mg, Mw 573
(free base), 0.002% dry wt) and 4′-hydroxyanopterine (3, tR = 18 min,
2.1 mg, Mw 557 (free base), 0.003% dry wt). Fraction 38 (m = 6.5 mg)
obtained from the ﬁrst isolation step was further puriﬁed by HPLC
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using a Betasil phenyl column with solvent conditions consisting of a
linear gradient from 35% MeCN (0.1% TFA)/65% H2O (0.1% TFA)
to 80% MeCN (0.1% TFA)/20% H2O (0.1% TFA) in 90 min at a ﬂow
rate of 9 mL/min to yield the TFA salts of 7β-hydroxyanopterine (6, tR
= 18 min, 1.9 mg, Mw 557 (free base), 0.003% dry wt) and 6α-
acetoxyanopterine (1, tR = 26 min, 1.1 mg, Mw 583 (free base), 0.002%
dry wt). Fraction 39 (m = 7.2 mg) obtained from the ﬁrst isolation
step was further puriﬁed by HPLC using a Betasil phenyl column with
solvent conditions consisting of a linear gradient from 35% MeCN
(0.1% TFA)/65% H2O (0.1% TFA) to 80% MeCN (0.1% TFA)/20%
H2O (0.1% TFA) in 90 min at a ﬂow rate of 9 mL/min to yield the
TFA salt of anopterine (5, tR = 29 min, 3.4 mg, Mw 541 (free base),
0.005% dry wt). Fraction 43 (m = 4.2 mg) from the ﬁrst isolation step
was further puriﬁed by HPLC using a Betasil phenyl column with
solvent conditions consisting of a linear gradient from 35% MeCN
(0.1% TFA)/65% H2O (0.1% TFA) to 80% MeCN (0.1% TFA)/20%
H2O (0.1% TFA) in 90 min at a ﬂow rate of 9 mL/min. Manual
collection yielded one pure compound as its TFA salt, 11α-
benzoylanopterine (4, tR = 24 min, 0.7 mg, Mw 563 (free base),
0.001% dry wt). Fraction 44 from the ﬁrst isolation step (m = 2.8 mg)
was further puriﬁed by HPLC using a Betasil phenyl column with
solvent conditions consisting of a linear gradient from 35% MeCN
(0.1% TFA)/65% H2O (0.1% TFA) to 80% MeCN (0.1% TFA)/20%
H2O (0.1% TFA) in 90 min at a ﬂow rate of 9 mL/min. Manual
collection yielded one pure compound as its TFA salt, 7β-hydroxy-
11α-benzoylanopterine (8, tR = 27 min, 0.4 mg, Mw 580 (free base),
0.001% dry wt).
The air-dried and ground leaves (270 g) of A. macleayanus were
sequentially extracted at room temperature with CH2Cl2 (1 L) and
MeOH (1 L × 3). The CH2Cl2 and MeOH extractions were combined
and dried under reduced pressure to yield a crude extract (95 g). The
chlorophyll of the MeOH/CH2Cl2 extract was removed by liquid/
liquid partition (n-hexane/H2O, 1:1, 800 mL × 3). The resulting
aqueous extract (∼60 g) was further puriﬁed using the system
CH2Cl2/H2O (1:1, 800 mL × 3). The CH2Cl2 extract (375 mg) was
resuspended in MeOH, preadsorbed to C18 silica, and packed into a
stainless steel guard cartridge. This cartridge was subsequently
attached to a semipreparative Betasil phenyl HPLC column. Linear
gradient conditions from 10% MeOH (0.1% TFA)/90% H2O (0.1%
TFA) to 100% MeOH (0.1% TFA) were performed for the ﬁrst 40
min; then conditions were held at 100% MeOH (0.1% TFA) for 20
min, at a ﬂow rate of 9 mL/min. Sixty fractions (60 × 1 min) were
collected from the start of the HPLC run. Fractions were analyzed by
(±)-LRESIMS in order to detect the ions belonging to the active
fractions previously identiﬁed. Fractions 25 and 26 were combined (m
= 32.1 mg) and further puriﬁed by HPLC using a Betasil phenyl
column with solvent conditions consisting of a linear gradient from
30% MeCN (0.1% TFA)/70% H2O (0.1% TFA) to 80% MeCN (0.1%
TFA)/20% H2O (0.1% TFA) in 60 min at a ﬂow rate of 9 mL/min
and aﬀorded the TFA salt of 4′-hydroxy-6α-acetoxyanopterine (2, tR =
15 min, 5.6 mg, Mw 599 (free base), 0.002% dry wt). Fractions 29 to
31 from the ﬁrst isolation step were combined (m = 44.7 mg) and
further puriﬁed by HPLC using a Betasil phenyl column with solvent
conditions consisting of a linear gradient from 30% MeCN (0.1%
TFA)/70% H2O (0.1% TFA) to 80% MeCN (0.1% TFA)/20% H2O
(0.1% TFA) in 60 min at a ﬂow rate of 9 mL/min and yielded the TFA
salt of 6α-acetoxyanopterine (1, tR = 21 min, 10.6 mg, Mw 583 (free
base), 0.004% dry wt).
TFA Salt of 6α-Acetoxyanopterine (1): stable yellow gum; [α]25D
+63 (c 0.1, MeOH); [α]25D −6 (c 0.2, CHCl3); UV λmax (MeOH) (log
ε) 210 (4.26) nm; 1H NMR (600 MHz, acetone-d6) see Table 1;
13C
NMR (150 MHz, acetone-d6) see Table 2; (+)-LRESIMS m/z 584
(100) [M − CF3COO−]+; (+)-HRESIMS m/z 584.3215
(C33H46NO8
+ [M − CF3COO−]+ requires 584.3218).
TFA Salt of 4′-Hydroxy-6α-acetoxyanopterine (2): stable yellow
gum; [α]25D +48 (c 0.04, MeOH); [α]
25
D +53 (c 0.03, CHCl3); UV
λmax (MeOH) (log ε) 206 (4.17) nm;
1H NMR (600 MHz, acetone-
d6), see Table 1;
13C NMR (150 MHz, acetone-d6), see Table 2;
(+)-LRESIMS m/z 600 (100) [M − CF3COO−]+; (+)-HRESIMS m/z
600.3171 (C33H46NO9
+ [M − CF3COO−]+ requires 600.3167).
TFA Salt of 4′-Hydroxyanopterine (3): stable yellow gum; [α]25D
+19 (c 0.05, MeOH); [α]25D +45 (c 0.01, CHCl3); UV λmax (MeOH)
(log ε) 209 (4.21) nm; 1H NMR (600 MHz, acetone-d6), see Table 1;
13C NMR (150 MHz, acetone-d6), see Table 2; (+)-LRESIMS m/z
558 (100) [M − CF3COO−]+; (+)-HRESIMS m/z 558.3067
(C31H44NO8
+ [M − CF3COO−]+ requires 558.3061).
TFA Salt of 11α-Benzoylanopterine (4): stable yellow gum; [α]25D
+6 (c 0.1, MeOH); [α]25D −92 (c 0.1, CHCl3); UV λmax (MeOH) (log
ε) 222 (4.03) nm; 1H NMR (600 MHz, acetone-d6), see Table 1;
13C
NMR (150 MHz, acetone-d6), see Table 2; (+)-LRESIMS m/z 564
(100) [M − CF3COO−]+; (+)-HRESIMS m/z 564.2959
(C33H42NO7
+ [M − CF3COO−]+ requires 564.2956).
TFA Salt of Anopterine (5): stable yellow gum; [α]25D +10 (c 0.1,
MeOH); [α]25D −5 (c 0.2, CHCl3); literature value for the free base of
5, [α]25D −12 (c 1.5, CHCl3);
2 UV λmax (MeOH) (log ε) 208 (4.13)
nm; (+)-LRESIMS m/z 542 (100) [M − CF3COO−]+.
TFA Salt of 7β-Hydroxyanopterine (6): stable yellow gum; [α]25D
+20 (c 0.03, CHCl3); [α]
25
D +15 (c 0.03, CHCl3/MeOH); literature
value for the free base of 6, [α]25D −12 (c 1.0, CHCl3/MeOH);
5 UV
λmax (MeOH) (log ε) 209 (4.39) nm; (+)-LRESIMS m/z 558 (100)
[M − CF3COO−]+.
TFA Salt of 7β,4′-Dihydroxyanopterine (7): stable yellow gum;
[α]25D +15 (c 0.01, CHCl3); [α]
25
D +19 (c 0.1, MeOH); literature
value for the free base of 7, [α]25D −9 (c 1.2, MeOH);5 UV λmax
(MeOH) (log ε) 209 (4.65) nm; (+)-LRESIMS m/z 574 (100) [M −
CF3COO
−]+.
TFA Salt of 7β-Hydroxy-11α-benzoylanopterine (8): stable yellow
gum; [α]25D +53 (c 0.01, CHCl3); [α]
25
D −50 (c 0.01, MeOH);
literature value for the free base of 8, [α]25D −10 (c 1.0, MeOH);10 UV
λmax (MeOH) (log ε) 226 (4.13) nm; (+)-LRESIMS m/z 580 (100)
[M − CF3COO−]+.
AlamarBlue and Live-Cell Imaging Assays. LNCaP and C4-2B
cells were obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). BPH-1 and WPMY-1 cells were kind
gifts from J. Clements (APCRC-Q, QUT, Australia). DuCaP cells were
a generous gift from M. Ness (VTT Technical Research Centre of
Finland). LNCaP, C4-2B, BPH-1, and WPMY-1 cells were cultured in
phenol-red-free RPMI-1640 medium (Thermo Fisher Scientiﬁc)
supplemented with 5% FBS (Thermo Fisher Scientiﬁc) at 37 °C in
an atmosphere containing 5% CO2 and maintained in log phase
growth. DuCaP cells were cultured in phenol-red free RPMI-1640
medium (Thermo Fisher Scientiﬁc) supplemented with 10% FBS
(Thermo Fisher Scientiﬁc) at 37 °C in an atmosphere containing 5%
CO2 and maintained in log phase growth. Cell viability as a function of
metabolic activity was measured by an AlamarBlue end point assay
(Thermo Fisher Scientiﬁc) as previously described.23 Brieﬂy, LNCaP
(4000 cells per well), C4-2B (3000 cells per well), DuCaP (15 000
cells per well), BPH-1 (3000 cells per well), and WPMY-1 (2000 cells
per well) were seeded for 24 h into 96-well tissue culture plates
(Corning, Corning, NY, USA) and treated with the indicated
compounds. Metabolic activity was measured with AlamarBlue
according to the manufacturer’s instructions (Thermo Fisher
Scientiﬁc) after 72 h of treatment. Fractions or compounds were
dissolved in DMSO and diluted in growth medium (ﬁnal
concentration 0.3%). The prefractionated library was screened at 10
μg/mL. Control cells were treated with the equivalent dose of DMSO
(negative control) or vinblastine (25 nM, Sigma-Aldrich) as positive
control. For live-cell imaging, cells were seeded and treated as above.
As described before,23 the 96-well plates were loaded into an IncuCyte
live-cell imaging system (Essen BioScience, Ann Arbor, MI, USA),
cells were imaged every 2 h for 72 h, and growth was measured as a
function of increasing conﬂuence. Calculations of half-maximal
inhibitory concentration (IC50) after 72 h of treatment were
performed with GraphPad Prism (GraphPad Software). Each data
point was performed in triplicate and repeated in at least three
independent experiments.
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